{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36810524", "DateCompleted": {"Year": "2023", "Month": "02", "Day": "24"}, "DateRevised": {"Year": "2023", "Month": "03", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "02", "Day": "21"}], "Language": ["eng"], "ELocationID": ["73", "10.1038/s41392-023-01353-3"], "Journal": {"ISSN": "2059-3635", "JournalIssue": {"Volume": "8", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Feb", "Day": "21"}}, "Title": "Signal transduction and targeted therapy", "ISOAbbreviation": "Signal Transduct Target Ther"}, "ArticleTitle": "Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions.", "Pagination": {"StartPage": "73", "MedlinePgn": "73"}, "Abstract": {"AbstractText": ["Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, and its treatment remains a big challenge. The pathogenesis of PD may be related to environmental and genetic factors, and exposure to toxins and gene mutations may be the beginning of brain lesions. The identified mechanisms of PD include \u03b1-synuclein aggregation, oxidative stress, ferroptosis, mitochondrial dysfunction, neuroinflammation, and gut dysbiosis. The interactions among these molecular mechanisms complicate the pathogenesis of PD and pose great challenges to drug development. At the same time, the diagnosis and detection of PD are also one of obstacles to the treatment of PD due to its long latency and complex mechanism. Most conventional therapeutic interventions for PD possess limited effects and have serious side effects, heightening the need to develop novel treatments for this disease. In this review, we systematically summarized the pathogenesis, especially the molecular mechanisms of PD, the classical research models, clinical diagnostic criteria, and the reported drug therapy strategies, as well as the newly reported drug candidates in clinical trials. We also shed light on the components derived from medicinal plants that are newly identified for their effects in PD treatment, with the expectation to provide the summary and outlook for developing the next generation of drugs and preparations for PD therapy."], "CopyrightInformation": "\u00a9 2023. The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China."}], "LastName": "Dong-Chen", "ForeName": "Xu", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China."}], "LastName": "Yong", "ForeName": "Chen", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China."}], "LastName": "Yang", "ForeName": "Xu", "Initials": "X"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China."}], "LastName": "Chen-Yu", "ForeName": "ShenTu", "Initials": "S"}, {"Identifier": ["0000-0001-9763-383X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China. lhpeng@zju.edu.cn."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, P. R. China. lhpeng@zju.edu.cn."}], "LastName": "Li-Hua", "ForeName": "Peng", "Initials": "P"}], "PublicationTypeList": ["Journal Article", "Review", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Signal Transduct Target Ther", "NlmUniqueID": "101676423", "ISSNLinking": "2059-3635"}, "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Parkinson Disease"}, {"QualifierName": [], "DescriptorName": "Neurodegenerative Diseases"}, {"QualifierName": [], "DescriptorName": "Oxidative Stress"}, {"QualifierName": [], "DescriptorName": "Mutation"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 390, 1211\u20131259 (2017).", "ArticleIdList": ["PMC5605509", "28919117"]}, {"Citation": "Parkinson J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 2002;14:223\u2013236. doi: 10.1176/jnp.14.2.223.", "ArticleIdList": ["10.1176/jnp.14.2.223", "11983801"]}, {"Citation": "Charcot, J. M. Lecons sur, les maladies du syst\u00e8me nerveux, Vol. 1 (Lecrosnier et Bab\u00e9, 1886)."}, {"Citation": "Przedborski S. The two-century journey of Parkinson disease research. Nat. Rev. Neurosci. 2017;18:251\u2013259. doi: 10.1038/nrn.2017.25.", "ArticleIdList": ["10.1038/nrn.2017.25", "28303016"]}, {"Citation": "Poewe W, et al. Parkinson disease. Nat. Rev. Dis. Prim. 2017;3:17013. doi: 10.1038/nrdp.2017.13.", "ArticleIdList": ["10.1038/nrdp.2017.13", "28332488"]}, {"Citation": "Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson\u2019s disease. Mov. Disord. 2003;18:19\u201331. doi: 10.1002/mds.10305.", "ArticleIdList": ["10.1002/mds.10305", "12518297"]}, {"Citation": "Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 2013;70:859\u2013866. doi: 10.1001/jamaneurol.2013.114.", "ArticleIdList": ["10.1001/jamaneurol.2013.114", "PMC3707980", "23689920"]}, {"Citation": "Van Den Eeden SK, et al. Incidence of Parkinson\u2019s disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 2003;157:1015\u20131022. doi: 10.1093/aje/kwg068.", "ArticleIdList": ["10.1093/aje/kwg068", "12777365"]}, {"Citation": "Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 2014;29:1583\u20131590. doi: 10.1002/mds.25945.", "ArticleIdList": ["10.1002/mds.25945", "24976103"]}, {"Citation": "Baldereschi M, et al. Parkinson\u2019s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55:1358\u20131363. doi: 10.1212/WNL.55.9.1358.", "ArticleIdList": ["10.1212/WNL.55.9.1358", "11087781"]}, {"Citation": "Kusumi M, Nakashima K, Harada H, Nakayama H, Takahashi K. Epidemiology of Parkinson\u2019s disease in Yonago City, Japan: comparison with a study carried out 12 years ago. Neuroepidemiology. 1996;15:201\u2013207. doi: 10.1159/000109908.", "ArticleIdList": ["10.1159/000109908", "8817502"]}, {"Citation": "Gordon PH, Mehal JM, Holman RC, Rowland AS, Cheek JE. Parkinson\u2019s disease among American Indians and Alaska natives: a nationwide prevalence study. Mov. Disord. 2012;27:1456\u20131459. doi: 10.1002/mds.25153.", "ArticleIdList": ["10.1002/mds.25153", "22893192"]}, {"Citation": "Morens DM, et al. Epidemiologic observations on Parkinson\u2019s disease: incidence and mortality in a prospective study of middle-aged men. Neurology. 1996;46:1044\u20131050. doi: 10.1212/WNL.46.4.1044.", "ArticleIdList": ["10.1212/WNL.46.4.1044", "8780088"]}, {"Citation": "Ascherio A, Schwarzschild MA. The epidemiology of Parkinson\u2019s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257\u20131272. doi: 10.1016/S1474-4422(16)30230-7.", "ArticleIdList": ["10.1016/S1474-4422(16)30230-7", "27751556"]}, {"Citation": "Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry. 1988;51:745\u2013752. doi: 10.1136/jnnp.51.6.745.", "ArticleIdList": ["10.1136/jnnp.51.6.745", "PMC1033142", "2841426"]}, {"Citation": "Marras C, Lang A. Parkinson\u2019s disease subtypes: lost in translation? J. Neurol. Neurosurg. Psychiatry. 2013;84:409\u2013415. doi: 10.1136/jnnp-2012-303455.", "ArticleIdList": ["10.1136/jnnp-2012-303455", "22952329"]}, {"Citation": "Jankovic J, et al. Variable expression of Parkinson\u2019s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40:1529\u20131534. doi: 10.1212/WNL.40.10.1529.", "ArticleIdList": ["10.1212/WNL.40.10.1529", "2215943"]}, {"Citation": "Khoo TK, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80:276\u2013281. doi: 10.1212/WNL.0b013e31827deb74.", "ArticleIdList": ["10.1212/WNL.0b013e31827deb74", "PMC3589180", "23319473"]}, {"Citation": "Postuma RB, et al. Identifying prodromal Parkinson\u2019s disease: pre-motor disorders in Parkinson\u2019s disease. Mov. Disord. 2012;27:617\u2013626. doi: 10.1002/mds.24996.", "ArticleIdList": ["10.1002/mds.24996", "22508280"]}, {"Citation": "Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years. Mov. Disord. 2005;20:190\u2013199. doi: 10.1002/mds.20324.", "ArticleIdList": ["10.1002/mds.20324", "15551331"]}, {"Citation": "Fearnley JM, Lees AJ. Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity. Brain. 1991;114:2283\u20132301. doi: 10.1093/brain/114.5.2283.", "ArticleIdList": ["10.1093/brain/114.5.2283", "1933245"]}, {"Citation": "Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain. 1999;122:1437\u20131448. doi: 10.1093/brain/122.8.1437.", "ArticleIdList": ["10.1093/brain/122.8.1437", "10430830"]}, {"Citation": "Dijkstra AA, et al. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson\u2019s disease. Mov. Disord. 2014;29:1244\u20131251. doi: 10.1002/mds.25952.", "ArticleIdList": ["10.1002/mds.25952", "24996051"]}, {"Citation": "Iacono D, et al. Parkinson disease and incidental Lewy body disease: Just a question of time? Neurology. 2015;85:1670\u20131679. doi: 10.1212/WNL.0000000000002102.", "ArticleIdList": ["10.1212/WNL.0000000000002102", "PMC4653112", "26468408"]}, {"Citation": "Braak H, et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging. 2003;24:197\u2013211. doi: 10.1016/S0197-4580(02)00065-9.", "ArticleIdList": ["10.1016/S0197-4580(02)00065-9", "12498954"]}, {"Citation": "Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson\u2019s disease. Nature. 1988;334:345\u2013348. doi: 10.1038/334345a0.", "ArticleIdList": ["10.1038/334345a0", "2899295"]}, {"Citation": "Hirsch EC, Orieux G, Muriel MP, Francois C, Feger J. Nondopaminergic neurons in Parkinson\u2019s disease. Adv. Neurol. 2003;91:29\u201337.", "ArticleIdList": ["12449099"]}, {"Citation": "Rizzo G, et al. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566\u2013576. doi: 10.1212/WNL.0000000000002350.", "ArticleIdList": ["10.1212/WNL.0000000000002350", "26764028"]}, {"Citation": "Postuma RB, et al. Validation of the MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov. Disord. 2018;33:1601\u20131608. doi: 10.1002/mds.27362.", "ArticleIdList": ["10.1002/mds.27362", "30145797"]}, {"Citation": "Krismer F, et al. Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. Parkinsonism Relat. Disord. 2017;35:36\u201341. doi: 10.1016/j.parkreldis.2016.11.010.", "ArticleIdList": ["10.1016/j.parkreldis.2016.11.010", "27890451"]}, {"Citation": "Katzenschlager R, Lees AJ. Olfaction and Parkinson\u2019s syndromes: its role in differential diagnosis. Curr. Opin. Neurol. 2004;17:417\u2013423. doi: 10.1097/01.wco.0000137531.76491.c2.", "ArticleIdList": ["10.1097/01.wco.0000137531.76491.c2", "15247536"]}, {"Citation": "Ohtsuka C, et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson\u2019s disease using neuromelanin-sensitive MR imaging. Neurosci. Lett. 2013;541:93\u201398. doi: 10.1016/j.neulet.2013.02.012.", "ArticleIdList": ["10.1016/j.neulet.2013.02.012", "23428505"]}, {"Citation": "Langkammer C, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage. 2012;62:1593\u20131599. doi: 10.1016/j.neuroimage.2012.05.049.", "ArticleIdList": ["10.1016/j.neuroimage.2012.05.049", "PMC3413885", "22634862"]}, {"Citation": "Ehrminger M, et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain. 2016;139:1180\u20131188. doi: 10.1093/brain/aww006.", "ArticleIdList": ["10.1093/brain/aww006", "26920675"]}, {"Citation": "Stoessl AJ, Lehericy S, Strafella AP. Imaging insights into basal ganglia function, Parkinson\u2019s disease, and dystonia. Lancet. 2014;384:532\u2013544. doi: 10.1016/S0140-6736(14)60041-6.", "ArticleIdList": ["10.1016/S0140-6736(14)60041-6", "PMC4454525", "24954673"]}, {"Citation": "Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat. Rev. Neurol. 2014;10:708\u2013722. doi: 10.1038/nrneurol.2014.205.", "ArticleIdList": ["10.1038/nrneurol.2014.205", "25385334"]}, {"Citation": "Kalinderi K, Bostantjopoulou S, Fidani L. The genetic background of Parkinson\u2019s disease: current progress and future prospects. Acta Neurol. Scand. 2016;134:314\u2013326. doi: 10.1111/ane.12563.", "ArticleIdList": ["10.1111/ane.12563", "26869347"]}, {"Citation": "Tambasco N, et al. A53T in a parkinsonian family: a clinical update of the SNCA phenotypes. J. Neural Transm. (Vienna) 2016;123:1301\u20131307. doi: 10.1007/s00702-016-1578-6.", "ArticleIdList": ["10.1007/s00702-016-1578-6", "27250986"]}, {"Citation": "Marras C, Canning CG, Goldman SM. Environment, lifestyle, and Parkinson\u2019s disease: Implications for prevention in the next decade. Mov. Disord. 2019;34:801\u2013811. doi: 10.1002/mds.27720.", "ArticleIdList": ["10.1002/mds.27720", "31091353"]}, {"Citation": "Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979\u2013980. doi: 10.1126/science.6823561.", "ArticleIdList": ["10.1126/science.6823561", "6823561"]}, {"Citation": "Tanner CM. Epidemiology of Parkinson\u2019s disease. Neurol. Clin. 1992;10:317\u2013329. doi: 10.1016/S0733-8619(18)30212-3.", "ArticleIdList": ["10.1016/S0733-8619(18)30212-3", "PMC7172502", "1584176"]}, {"Citation": "Ikeuchi T, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch. Neurol. 2008;65:514\u2013519. doi: 10.1001/archneur.65.4.514.", "ArticleIdList": ["10.1001/archneur.65.4.514", "18413475"]}, {"Citation": "Morgado HV, Vilatela MEA, L\u00f3pez ML. The role of genetics in Parkinson\u2019s disease. Salud Ment. 2007;30:16\u201324."}, {"Citation": "Monfrini E, Di Fonzo A. Leucine-rich repeat kinase (LRRK2) genetics and Parkinson\u2019s disease. Adv. Neurobiol. 2017;14:3\u201330. doi: 10.1007/978-3-319-49969-7_1.", "ArticleIdList": ["10.1007/978-3-319-49969-7_1", "28353276"]}, {"Citation": "Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev. 2018;42:72\u201385. doi: 10.1016/j.arr.2017.12.007.", "ArticleIdList": ["10.1016/j.arr.2017.12.007", "29288112"]}, {"Citation": "Hedrich K, et al. Recurrent LRRK2 (Park8) mutations in early-onset Parkinson\u2019s disease. Mov. Disord. 2006;21:1506\u20131510. doi: 10.1002/mds.20990.", "ArticleIdList": ["10.1002/mds.20990", "16758483"]}, {"Citation": "Martins LM, et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell Biol. 2004;24:9848\u20139862. doi: 10.1128/MCB.24.22.9848-9862.2004.", "ArticleIdList": ["10.1128/MCB.24.22.9848-9862.2004", "PMC525490", "15509788"]}, {"Citation": "Plun-Favreau H, et al. The mitochondrial protease HtrA2 is regulated by Parkinson\u2019s disease-associated kinase PINK1. Nat. Cell Biol. 2007;9:1243\u20131252. doi: 10.1038/ncb1644.", "ArticleIdList": ["10.1038/ncb1644", "17906618"]}, {"Citation": "Moisoi N, et al. Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation of a brain-specific transcriptional stress response. Cell Death Differ. 2009;16:449\u2013464. doi: 10.1038/cdd.2008.166.", "ArticleIdList": ["10.1038/cdd.2008.166", "19023330"]}, {"Citation": "Fitzgerald JC, et al. Phosphorylation of HtrA2 by cyclin-dependent kinase-5 is important for mitochondrial function. Cell Death Differ. 2012;19:257\u2013266. doi: 10.1038/cdd.2011.90.", "ArticleIdList": ["10.1038/cdd.2011.90", "PMC3191116", "21701498"]}, {"Citation": "Basak I, et al. Arabidopsis AtPARK13, which confers thermotolerance, targets misfolded proteins. J. Biol. Chem. 2014;289:14458\u201314469. doi: 10.1074/jbc.M114.548156.", "ArticleIdList": ["10.1074/jbc.M114.548156", "PMC4031502", "24719325"]}, {"Citation": "Bonifacino JS, Hurley JH. Retromer. Curr. Opin. Cell Biol. 2008;20:427\u2013436. doi: 10.1016/j.ceb.2008.03.009.", "ArticleIdList": ["10.1016/j.ceb.2008.03.009", "PMC2833274", "18472259"]}, {"Citation": "Arighi CN, Hartnell LM, Aguilar RC, Haft CR, Bonifacino JS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J. Cell Biol. 2004;165:123\u2013133. doi: 10.1083/jcb.200312055.", "ArticleIdList": ["10.1083/jcb.200312055", "PMC2172094", "15078903"]}, {"Citation": "Chartier-Harlin MC, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am. J. Hum. Genet. 2011;89:398\u2013406. doi: 10.1016/j.ajhg.2011.08.009.", "ArticleIdList": ["10.1016/j.ajhg.2011.08.009", "PMC3169825", "21907011"]}, {"Citation": "Deng H, Wu Y, Jankovic J. The EIF4G1 gene and Parkinson\u2019s disease. Acta Neurol. Scand. 2015;132:73\u201378. doi: 10.1111/ane.12397.", "ArticleIdList": ["10.1111/ane.12397", "25765080"]}, {"Citation": "Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136:731\u2013745. doi: 10.1016/j.cell.2009.01.042.", "ArticleIdList": ["10.1016/j.cell.2009.01.042", "PMC3610329", "19239892"]}, {"Citation": "Hattori N, Mizuno Y. Twenty years since the discovery of the parkin gene. J. Neural Transm. 2017;124:1037\u20131054. doi: 10.1007/s00702-017-1742-7.", "ArticleIdList": ["10.1007/s00702-017-1742-7", "28620835"]}, {"Citation": "Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 2007;6:652\u2013662. doi: 10.1016/S1474-4422(07)70174-6.", "ArticleIdList": ["10.1016/S1474-4422(07)70174-6", "17582365"]}, {"Citation": "Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson\u2019s disease. Neuron. 2015;85:257\u2013273. doi: 10.1016/j.neuron.2014.12.007.", "ArticleIdList": ["10.1016/j.neuron.2014.12.007", "PMC4764997", "25611507"]}, {"Citation": "Seirafi M, Kozlov G, Gehring K. Parkin structure and function. FEBS J. 2015;282:2076\u20132088. doi: 10.1111/febs.13249.", "ArticleIdList": ["10.1111/febs.13249", "PMC4672691", "25712550"]}, {"Citation": "van der Merwe C, Jalali Sefid Dashti Z, Christoffels A, Loos B, Bardien S. Evidence for a common biological pathway linking three Parkinson\u2019s disease-causing genes: parkin, PINK1 and DJ-1. Eur. J. Neurosci. 2015;41:1113\u20131125. doi: 10.1111/ejn.12872.", "ArticleIdList": ["10.1111/ejn.12872", "25761903"]}, {"Citation": "Wilhelmus MM, Nijland PG, Drukarch B, de Vries HE, van Horssen J. Involvement and interplay of Parkin, PINK1, and DJ1 in neurodegenerative and neuroinflammatory disorders. Free Radic. Biol. Med. 2012;53:983\u2013992. doi: 10.1016/j.freeradbiomed.2012.05.040.", "ArticleIdList": ["10.1016/j.freeradbiomed.2012.05.040", "22687462"]}, {"Citation": "Zondler L, et al. DJ-1 interactions with \u03b1-synuclein attenuate aggregation and cellular toxicity in models of Parkinson\u2019s disease. Cell Death Dis. 2014;5:e1350. doi: 10.1038/cddis.2014.307.", "ArticleIdList": ["10.1038/cddis.2014.307", "PMC4123098", "25058424"]}, {"Citation": "Demirsoy S, et al. ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function. Hum. Mol. Genet. 2017;26:1656\u20131669. doi: 10.1093/hmg/ddx070.", "ArticleIdList": ["10.1093/hmg/ddx070", "28334751"]}, {"Citation": "Holemans T, et al. A lipid switch unlocks Parkinson\u2019s disease-associated ATP13A2. Proc. Natl Acad. Sci. USA. 2015;112:9040\u20139045. doi: 10.1073/pnas.1508220112.", "ArticleIdList": ["10.1073/pnas.1508220112", "PMC4517210", "26134396"]}, {"Citation": "Park JS, Koentjoro B, Veivers D, Mackay-Sim A, Sue CM. Parkinson\u2019s disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum. Mol. Genet. 2014;23:2802\u20132815. doi: 10.1093/hmg/ddt623.", "ArticleIdList": ["10.1093/hmg/ddt623", "PMC4014187", "24399444"]}, {"Citation": "Tsunemi T, Krainc D. Zn2+ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum. Mol. Genet. 2014;23:2791\u20132801. doi: 10.1093/hmg/ddt572.", "ArticleIdList": ["10.1093/hmg/ddt572", "PMC4014186", "24334770"]}, {"Citation": "Park JS, Blair NF, Sue CM. The role of ATP13A2 in Parkinson\u2019s disease: clinical phenotypes and molecular mechanisms. Mov. Disord. 2015;30:770\u2013779. doi: 10.1002/mds.26243.", "ArticleIdList": ["10.1002/mds.26243", "25900096"]}, {"Citation": "Kong SM, et al. Parkinson\u2019s disease-linked human PARK9/ATP13A2 maintains zinc homeostasis and promotes \u03b1-Synuclein externalization via exosomes. Hum. Mol. Genet. 2014;23:2816\u20132833. doi: 10.1093/hmg/ddu099.", "ArticleIdList": ["10.1093/hmg/ddu099", "24603074"]}, {"Citation": "Teixeira FR, et al. Gsk3\u03b2 and Tomm20 are substrates of the SCFFbxo7/PARK15 ubiquitin ligase associated with Parkinson\u2019s disease. Biochem J. 2016;473:3563\u20133580. doi: 10.1042/BCJ20160387.", "ArticleIdList": ["10.1042/BCJ20160387", "PMC5260939", "27503909"]}, {"Citation": "Ordureau A, et al. Defining roles of PARKIN and ubiquitin phosphorylation by PINK1 in mitochondrial quality control using a ubiquitin replacement strategy. Proc. Natl Acad. Sci. USA. 2015;112:6637\u20136642. doi: 10.1073/pnas.1506593112.", "ArticleIdList": ["10.1073/pnas.1506593112", "PMC4450373", "25969509"]}, {"Citation": "Duarte FV, et al. Adenosine receptors: regulatory players in the preservation of mitochondrial function induced by ischemic preconditioning of rat liver. Purinergic Signal. 2017;13:179\u2013190. doi: 10.1007/s11302-016-9548-x.", "ArticleIdList": ["10.1007/s11302-016-9548-x", "PMC5432478", "27848069"]}, {"Citation": "Baines CP, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658\u2013662. doi: 10.1038/nature03434.", "ArticleIdList": ["10.1038/nature03434", "15800627"]}, {"Citation": "Zhou ZD, Lee JCT, Tan EK. Pathophysiological mechanisms linking F-box only protein 7 (FBXO7) and Parkinson\u2019s disease (PD) Mutat. Res Rev. Mutat. Res. 2018;778:72\u201378. doi: 10.1016/j.mrrev.2018.10.001.", "ArticleIdList": ["10.1016/j.mrrev.2018.10.001", "30454685"]}, {"Citation": "Delgado-Camprubi M, Esteras N, Soutar MP, Plun-Favreau H, Abramov AY. Deficiency of Parkinson\u2019s disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation. Cell Death Differ. 2017;24:120\u2013131. doi: 10.1038/cdd.2016.104.", "ArticleIdList": ["10.1038/cdd.2016.104", "PMC5260490", "27689878"]}, {"Citation": "Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson\u2019s disease: insights from animal models. Nat. Rev. Neurosci. 2003;4:727\u2013738. doi: 10.1038/nrn1199.", "ArticleIdList": ["10.1038/nrn1199", "12951565"]}, {"Citation": "Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. Pathological roles of \u03b1-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015\u20131025. doi: 10.1016/S1474-4422(11)70213-7.", "ArticleIdList": ["10.1016/S1474-4422(11)70213-7", "22014436"]}, {"Citation": "Wales P, Pinho R, L\u00e1zaro DF, Outeiro TF. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. J. Parkinsons Dis. 2013;3:415\u2013459. doi: 10.3233/JPD-130216.", "ArticleIdList": ["10.3233/JPD-130216", "24270242"]}, {"Citation": "Burr\u00e9 J. The synaptic function of \u03b1-synuclein. J. Parkinsons Dis. 2015;5:699\u2013713. doi: 10.3233/JPD-150642.", "ArticleIdList": ["10.3233/JPD-150642", "PMC4927875", "26407041"]}, {"Citation": "Ruip\u00e9rez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson\u2019s disease. Prog. Lipid Res. 2010;49:420\u2013428. doi: 10.1016/j.plipres.2010.05.004.", "ArticleIdList": ["10.1016/j.plipres.2010.05.004", "20580911"]}, {"Citation": "Kim C, Lee SJ. Controlling the mass action of alpha-synuclein in Parkinson\u2019s disease. J. Neurochem. 2008;107:303\u2013316. doi: 10.1111/j.1471-4159.2008.05612.x.", "ArticleIdList": ["10.1111/j.1471-4159.2008.05612.x", "18691382"]}, {"Citation": "Melki R. Role of different alpha-synuclein strains in synucleinopathies, similarities with other neurodegenerative diseases. J. Parkinsons Dis. 2015;5:217\u2013227. doi: 10.3233/JPD-150543.", "ArticleIdList": ["10.3233/JPD-150543", "PMC4923763", "25757830"]}, {"Citation": "Kaushik S, Cuervo AM. Proteostasis and aging. Nat. Med. 2015;21:1406\u20131415. doi: 10.1038/nm.4001.", "ArticleIdList": ["10.1038/nm.4001", "26646497"]}, {"Citation": "Xilouri M, Brekk OR, Stefanis L. \u03b1-Synuclein and protein degradation systems: a reciprocal relationship. Mol. Neurobiol. 2013;47:537\u2013551. doi: 10.1007/s12035-012-8341-2.", "ArticleIdList": ["10.1007/s12035-012-8341-2", "22941029"]}, {"Citation": "Brieger K, Schiavone S, Miller FJ, Jr, Krause KH. Reactive oxygen species: from health to disease. Swiss Med. Wkly. 2012;142:w13659.", "ArticleIdList": ["22903797"]}, {"Citation": "Lee DH, Gold R, Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int. J. Mol. Sci. 2012;13:11783\u201311803. doi: 10.3390/ijms130911783.", "ArticleIdList": ["10.3390/ijms130911783", "PMC3472775", "23109883"]}, {"Citation": "Shukla V, Mishra SK, Pant HC. Oxidative stress in neurodegeneration. Adv. Pharm. Sci. 2011;2011:572634.", "ArticleIdList": ["PMC3177364", "21941533"]}, {"Citation": "Kemppainen S, et al. Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer\u2019s disease as well as in wild-type mice. Behav. Brain Res. 2015;291:1\u201311. doi: 10.1016/j.bbr.2015.05.002.", "ArticleIdList": ["10.1016/j.bbr.2015.05.002", "25975173"]}, {"Citation": "Melief EJ, et al. Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer\u2019s disease. J. Neurosci. Res. 2015;93:1413\u20131422. doi: 10.1002/jnr.23592.", "ArticleIdList": ["10.1002/jnr.23592", "PMC4504797", "25824456"]}, {"Citation": "Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007;87:245\u2013313. doi: 10.1152/physrev.00044.2005.", "ArticleIdList": ["10.1152/physrev.00044.2005", "17237347"]}, {"Citation": "Halliwell B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 2006;97:1634\u20131658. doi: 10.1111/j.1471-4159.2006.03907.x.", "ArticleIdList": ["10.1111/j.1471-4159.2006.03907.x", "16805774"]}, {"Citation": "Kovac S, et al. Nrf2 regulates ROS production by mitochondria and NADPH oxidase. Biochim Biophys. Acta. 2015;1850:794\u2013801. doi: 10.1016/j.bbagen.2014.11.021.", "ArticleIdList": ["10.1016/j.bbagen.2014.11.021", "PMC4471129", "25484314"]}, {"Citation": "Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog. Neurobiol. 2013;106-107:17\u201332. doi: 10.1016/j.pneurobio.2013.04.004.", "ArticleIdList": ["10.1016/j.pneurobio.2013.04.004", "PMC3742021", "23643800"]}, {"Citation": "Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann. N. Y Acad. Sci. 2008;1147:37\u201352. doi: 10.1196/annals.1427.015.", "ArticleIdList": ["10.1196/annals.1427.015", "PMC2869479", "19076429"]}, {"Citation": "Dion\u00edsio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinson\u2019s disease. Ageing Res. Rev. 2021;67:101263. doi: 10.1016/j.arr.2021.101263.", "ArticleIdList": ["10.1016/j.arr.2021.101263", "33540042"]}, {"Citation": "Guiney SJ, Adlard PA, Bush AI, Finkelstein DI, Ayton S. Ferroptosis and cell death mechanisms in Parkinson\u2019s disease. Neurochem. Int. 2017;104:34\u201348. doi: 10.1016/j.neuint.2017.01.004.", "ArticleIdList": ["10.1016/j.neuint.2017.01.004", "28082232"]}, {"Citation": "Kagan VE, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 2017;13:81\u201390. doi: 10.1038/nchembio.2238.", "ArticleIdList": ["10.1038/nchembio.2238", "PMC5506843", "27842066"]}, {"Citation": "Dehay B, et al. Pathogenic lysosomal depletion in Parkinson\u2019s disease. J. Neurosci. 2010;30:12535\u201312544. doi: 10.1523/JNEUROSCI.1920-10.2010.", "ArticleIdList": ["10.1523/JNEUROSCI.1920-10.2010", "PMC6633458", "20844148"]}, {"Citation": "Hernandes MS, Caf\u00e9-Mendes CC, Britto LR. NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice. Oxid. Med. Cell Longev. 2013;2013:157857. doi: 10.1155/2013/157857.", "ArticleIdList": ["10.1155/2013/157857", "PMC3863573", "24379900"]}, {"Citation": "Dryanovski DI, et al. Calcium entry and \u03b1-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 2013;33:10154\u201310164. doi: 10.1523/JNEUROSCI.5311-12.2013.", "ArticleIdList": ["10.1523/JNEUROSCI.5311-12.2013", "PMC3682382", "23761910"]}, {"Citation": "Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060\u20131072. doi: 10.1016/j.cell.2012.03.042.", "ArticleIdList": ["10.1016/j.cell.2012.03.042", "PMC3367386", "22632970"]}, {"Citation": "Do Van B, et al. Ferroptosis, a newly characterized form of cell death in Parkinson\u2019s disease that is regulated by PKC. Neurobiol. Dis. 2016;94:169\u2013178. doi: 10.1016/j.nbd.2016.05.011.", "ArticleIdList": ["10.1016/j.nbd.2016.05.011", "27189756"]}, {"Citation": "Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 2014;16:1180\u20131191. doi: 10.1038/ncb3064.", "ArticleIdList": ["10.1038/ncb3064", "PMC4894846", "25402683"]}, {"Citation": "Skouta R, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 2014;136:4551\u20134556. doi: 10.1021/ja411006a.", "ArticleIdList": ["10.1021/ja411006a", "PMC3985476", "24592866"]}, {"Citation": "Cao J, et al. DJ-1 suppresses ferroptosis through preserving the activity of S-adenosyl homocysteine hydrolase. Nat. Commun. 2020;11:1251. doi: 10.1038/s41467-020-15109-y.", "ArticleIdList": ["10.1038/s41467-020-15109-y", "PMC7060199", "32144268"]}, {"Citation": "Forcina GC, Dixon SJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics. 2019;19:e1800311. doi: 10.1002/pmic.201800311.", "ArticleIdList": ["10.1002/pmic.201800311", "30888116"]}, {"Citation": "Cozza G, et al. Glutathione peroxidase 4-catalyzed reduction of lipid hydroperoxides in membranes: the polar head of membrane phospholipids binds the enzyme and addresses the fatty acid hydroperoxide group toward the redox center. Free Radic. Biol. Med. 2017;112:1\u201311. doi: 10.1016/j.freeradbiomed.2017.07.010.", "ArticleIdList": ["10.1016/j.freeradbiomed.2017.07.010", "28709976"]}, {"Citation": "Castellani RJ, Siedlak SL, Perry G, Smith MA. Sequestration of iron by Lewy bodies in Parkinson\u2019s disease. Acta Neuropathol. 2000;100:111\u2013114. doi: 10.1007/s004010050001.", "ArticleIdList": ["10.1007/s004010050001", "10963356"]}, {"Citation": "Golts N, et al. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 2002;277:16116\u201316123. doi: 10.1074/jbc.M107866200.", "ArticleIdList": ["10.1074/jbc.M107866200", "11850416"]}, {"Citation": "Guo JJ, et al. Intranasal administration of \u03b1-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis. Cell Death Dis. 2021;12:81. doi: 10.1038/s41419-020-03369-x.", "ArticleIdList": ["10.1038/s41419-020-03369-x", "PMC7807015", "33441545"]}, {"Citation": "Kenkhuis B, et al. Iron loading is a prominent feature of activated microglia in Alzheimer\u2019s disease patients. Acta Neuropathol. Commun. 2021;9:27. doi: 10.1186/s40478-021-01126-5.", "ArticleIdList": ["10.1186/s40478-021-01126-5", "PMC7887813", "33597025"]}, {"Citation": "Friedrich I, et al. Cell specific quantitative iron mapping on brain slices by immuno-\u00b5PIXE in healthy elderly and Parkinson\u2019s disease. Acta Neuropathol. Commun. 2021;9:47. doi: 10.1186/s40478-021-01145-2.", "ArticleIdList": ["10.1186/s40478-021-01145-2", "PMC7986300", "33752749"]}, {"Citation": "Healy S, McMahon J, Owens P, FitzGerald U. Significant glial alterations in response to iron loading in a novel organotypic hippocampal slice culture model. Sci. Rep. 2016;6:36410. doi: 10.1038/srep36410.", "ArticleIdList": ["10.1038/srep36410", "PMC5093415", "27808258"]}, {"Citation": "Wang J, Song N, Jiang H, Wang J, Xie J. Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons. Biochim Biophys. Acta. 2013;1832:618\u2013625. doi: 10.1016/j.bbadis.2013.01.021.", "ArticleIdList": ["10.1016/j.bbadis.2013.01.021", "23376588"]}, {"Citation": "Urrutia P, et al. Inflammation alters the expression of DMT1, FPN1 and hepcidin, and it causes iron accumulation in central nervous system cells. J. Neurochem. 2013;126:541\u2013549. doi: 10.1111/jnc.12244.", "ArticleIdList": ["10.1111/jnc.12244", "23506423"]}, {"Citation": "Sharma N, Nehru B. Apocyanin, a microglial NADPH oxidase inhibitor prevents dopaminergic neuronal degeneration in lipopolysaccharide-induced Parkinson\u2019s disease model. Mol. Neurobiol. 2016;53:3326\u20133337. doi: 10.1007/s12035-015-9267-2.", "ArticleIdList": ["10.1007/s12035-015-9267-2", "26081143"]}, {"Citation": "Kapralov AA, et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat. Chem. Biol. 2020;16:278\u2013290. doi: 10.1038/s41589-019-0462-8.", "ArticleIdList": ["10.1038/s41589-019-0462-8", "PMC7233108", "32080625"]}, {"Citation": "Xu H, et al. New progress on the role of glia in iron metabolism and iron-induced degeneration of dopamine neurons in Parkinson\u2019s disease. Front. Mol. Neurosci. 2017;10:455. doi: 10.3389/fnmol.2017.00455.", "ArticleIdList": ["10.3389/fnmol.2017.00455", "PMC5780449", "29403352"]}, {"Citation": "Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J. Biol. Chem. 2003;278:27144\u201327148. doi: 10.1074/jbc.M301988200.", "ArticleIdList": ["10.1074/jbc.M301988200", "12743117"]}, {"Citation": "Ayton S, et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann. Neurol. 2013;73:554\u2013559. doi: 10.1002/ana.23817.", "ArticleIdList": ["10.1002/ana.23817", "23424051"]}, {"Citation": "Wang J, Bi M, Xie J. Ceruloplasmin is involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Cell Mol. Neurobiol. 2015;35:661\u2013668. doi: 10.1007/s10571-015-0161-2.", "ArticleIdList": ["10.1007/s10571-015-0161-2", "25656940"]}, {"Citation": "Fern\u00e1ndez-Mend\u00edvil C, et al. Protective role of microglial HO-1 blockade in aging: implication of iron metabolism. Redox Biol. 2021;38:101789. doi: 10.1016/j.redox.2020.101789.", "ArticleIdList": ["10.1016/j.redox.2020.101789", "PMC7680814", "33212416"]}, {"Citation": "Song W, et al. Parkinsonian features in aging GFAP.HMOX1 transgenic mice overexpressing human HO-1 in the astroglial compartment. Neurobiol. Aging. 2017;58:163\u2013179. doi: 10.1016/j.neurobiolaging.2017.06.017.", "ArticleIdList": ["10.1016/j.neurobiolaging.2017.06.017", "28746897"]}, {"Citation": "Wang ZL, Yuan L, Li W, Li JY. Ferroptosis in Parkinson\u2019s disease: glia-neuron crosstalk. Trends Mol. Med. 2022;28:258\u2013269. doi: 10.1016/j.molmed.2022.02.003.", "ArticleIdList": ["10.1016/j.molmed.2022.02.003", "35260343"]}, {"Citation": "Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N. Engl. J. Med. 1985;312:1418\u20131421. doi: 10.1056/NEJM198505303122203.", "ArticleIdList": ["10.1056/NEJM198505303122203", "2581135"]}, {"Citation": "Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann. N. Y Acad. Sci. 2008;1147:395\u2013412. doi: 10.1196/annals.1427.027.", "ArticleIdList": ["10.1196/annals.1427.027", "PMC2605644", "19076459"]}, {"Citation": "Panov A, et al. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 2005;280:42026\u201342035. doi: 10.1074/jbc.M508628200.", "ArticleIdList": ["10.1074/jbc.M508628200", "16243845"]}, {"Citation": "Borland MK, et al. Chronic, low-dose rotenone reproduces Lewy neurites found in early stages of Parkinson\u2019s disease, reduces mitochondrial movement and slowly kills differentiated SH-SY5Y neural cells. Mol. Neurodegener. 2008;3:21. doi: 10.1186/1750-1326-3-21.", "ArticleIdList": ["10.1186/1750-1326-3-21", "PMC2631511", "19114014"]}, {"Citation": "Dauer W, Przedborski S. Parkinson\u2019s disease: mechanisms and models. Neuron. 2003;39:889\u2013909. doi: 10.1016/S0896-6273(03)00568-3.", "ArticleIdList": ["10.1016/S0896-6273(03)00568-3", "12971891"]}, {"Citation": "Klivenyi P, et al. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 2006;21:541\u2013548. doi: 10.1016/j.nbd.2005.08.018.", "ArticleIdList": ["10.1016/j.nbd.2005.08.018", "16298531"]}, {"Citation": "Thomas B, Beal MF. Parkinson\u2019s disease. Hum. Mol. Genet. 2007;16:R183\u2013R194. doi: 10.1093/hmg/ddm159.", "ArticleIdList": ["10.1093/hmg/ddm159", "17911161"]}, {"Citation": "Mud\u00f2 G, et al. Transgenic expression and activation of PGC-1\u03b1 protect dopaminergic neurons in the MPTP mouse model of Parkinson\u2019s disease. Cell Mol. Life Sci. 2012;69:1153\u20131165. doi: 10.1007/s00018-011-0850-z.", "ArticleIdList": ["10.1007/s00018-011-0850-z", "21984601"]}, {"Citation": "St-Pierre J, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127:397\u2013408. doi: 10.1016/j.cell.2006.09.024.", "ArticleIdList": ["10.1016/j.cell.2006.09.024", "17055439"]}, {"Citation": "Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787\u2013795. doi: 10.1038/nature05292.", "ArticleIdList": ["10.1038/nature05292", "17051205"]}, {"Citation": "Casarejos MJ, et al. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem. 2006;97:934\u2013946. doi: 10.1111/j.1471-4159.2006.03777.x.", "ArticleIdList": ["10.1111/j.1471-4159.2006.03777.x", "16573651"]}, {"Citation": "Palacino JJ, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004;279:18614\u201318622. doi: 10.1074/jbc.M401135200.", "ArticleIdList": ["10.1074/jbc.M401135200", "14985362"]}, {"Citation": "Liu G, et al. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009;454:187\u2013192. doi: 10.1016/j.neulet.2009.02.056.", "ArticleIdList": ["10.1016/j.neulet.2009.02.056", "19429081"]}, {"Citation": "Bertolin G, et al. The TOMM machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance. Autophagy. 2013;9:1801\u20131817. doi: 10.4161/auto.25884.", "ArticleIdList": ["10.4161/auto.25884", "24149440"]}, {"Citation": "Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 2008;183:795\u2013803. doi: 10.1083/jcb.200809125.", "ArticleIdList": ["10.1083/jcb.200809125", "PMC2592826", "19029340"]}, {"Citation": "Geisler S, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010;12:119\u2013131. doi: 10.1038/ncb2012.", "ArticleIdList": ["10.1038/ncb2012", "20098416"]}, {"Citation": "Matsuda N, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 2010;189:211\u2013221. doi: 10.1083/jcb.200910140.", "ArticleIdList": ["10.1083/jcb.200910140", "PMC2856912", "20404107"]}, {"Citation": "Narendra DP, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010;8:e1000298. doi: 10.1371/journal.pbio.1000298.", "ArticleIdList": ["10.1371/journal.pbio.1000298", "PMC2811155", "20126261"]}, {"Citation": "Vives-Bauza C, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl Acad. Sci. USA. 2010;107:378\u2013383. doi: 10.1073/pnas.0911187107.", "ArticleIdList": ["10.1073/pnas.0911187107", "PMC2806779", "19966284"]}, {"Citation": "Liu W, et al. SHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice. Signal Transduct. Target Ther. 2021;6:34. doi: 10.1038/s41392-021-00474-x.", "ArticleIdList": ["10.1038/s41392-021-00474-x", "PMC7846847", "33514686"]}, {"Citation": "Lavara-Culebras E, Paricio N. Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. Gene. 2007;400:158\u2013165. doi: 10.1016/j.gene.2007.06.013.", "ArticleIdList": ["10.1016/j.gene.2007.06.013", "17651920"]}, {"Citation": "Irrcher I, et al. Loss of the Parkinson\u2019s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum. Mol. Genet. 2010;19:3734\u20133746. doi: 10.1093/hmg/ddq288.", "ArticleIdList": ["10.1093/hmg/ddq288", "20639397"]}, {"Citation": "Krebiehl G, et al. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson\u2019s disease-associated protein DJ-1. PLoS ONE. 2010;5:e9367. doi: 10.1371/journal.pone.0009367.", "ArticleIdList": ["10.1371/journal.pone.0009367", "PMC2826413", "20186336"]}, {"Citation": "Saha S, et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009;29:9210\u20139218. doi: 10.1523/JNEUROSCI.2281-09.2009.", "ArticleIdList": ["10.1523/JNEUROSCI.2281-09.2009", "PMC3127548", "19625511"]}, {"Citation": "Yue M, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol. Dis. 2015;78:172\u2013195. doi: 10.1016/j.nbd.2015.02.031.", "ArticleIdList": ["10.1016/j.nbd.2015.02.031", "PMC4526103", "25836420"]}, {"Citation": "Wang X, et al. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum. Mol. Genet. 2012;21:1931\u20131944. doi: 10.1093/hmg/dds003.", "ArticleIdList": ["10.1093/hmg/dds003", "PMC3315202", "22228096"]}, {"Citation": "Mogi M, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from Parkinsonian patients. Neurosci. Lett. 1994;180:147\u2013150. doi: 10.1016/0304-3940(94)90508-8.", "ArticleIdList": ["10.1016/0304-3940(94)90508-8", "7700568"]}, {"Citation": "Mogi M, et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 1994;165:208\u2013210. doi: 10.1016/0304-3940(94)90746-3.", "ArticleIdList": ["10.1016/0304-3940(94)90746-3", "8015728"]}, {"Citation": "Mogi M, et al. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson\u2019s disease. Neurosci. Lett. 1995;193:129\u2013132. doi: 10.1016/0304-3940(95)11686-Q.", "ArticleIdList": ["10.1016/0304-3940(95)11686-Q", "7478158"]}, {"Citation": "Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J. Neural Transm. 1996;103:1077\u20131081. doi: 10.1007/BF01291792.", "ArticleIdList": ["10.1007/BF01291792", "9013395"]}, {"Citation": "Sommer A, et al. Infiltrating T lymphocytes reduce myeloid phagocytosis activity in synucleinopathy model. J. Neuroinflammation. 2016;13:174. doi: 10.1186/s12974-016-0632-5.", "ArticleIdList": ["10.1186/s12974-016-0632-5", "PMC4929755", "27364890"]}, {"Citation": "Brochard V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Investig. 2009;119:182\u2013192.", "ArticleIdList": ["PMC2613467", "19104149"]}, {"Citation": "Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson\u2019s disease. Antioxid. Redox Signal. 2009;11:2151\u20132166. doi: 10.1089/ars.2009.2460.", "ArticleIdList": ["10.1089/ars.2009.2460", "PMC2788126", "19243239"]}, {"Citation": "Kustrimovic N, et al. Parkinson\u2019s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-na\u00efve and drug-treated patients. J. Neuroinflammation. 2018;15:205. doi: 10.1186/s12974-018-1248-8.", "ArticleIdList": ["10.1186/s12974-018-1248-8", "PMC6044047", "30001736"]}, {"Citation": "Panicker N, et al. Fyn kinase regulates misfolded \u03b1-synuclein uptake and NLRP3 inflammasome activation in microglia. J. Exp. Med. 2019;216:1411\u20131430. doi: 10.1084/jem.20182191.", "ArticleIdList": ["10.1084/jem.20182191", "PMC6547864", "31036561"]}, {"Citation": "Ferreira SA, Romero-Ramos M. Microglia response during Parkinson\u2019s disease: alpha-synuclein intervention. Front. Cell Neurosci. 2018;12:247. doi: 10.3389/fncel.2018.00247.", "ArticleIdList": ["10.3389/fncel.2018.00247", "PMC6087878", "30127724"]}, {"Citation": "Ouchi Y, et al. Microglial activation and dopamine terminal loss in early Parkinson\u2019s disease. Ann. Neurol. 2005;57:168\u2013175. doi: 10.1002/ana.20338.", "ArticleIdList": ["10.1002/ana.20338", "15668962"]}, {"Citation": "Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 2009;15:S200\u2013S204. doi: 10.1016/S1353-8020(09)70814-4.", "ArticleIdList": ["10.1016/S1353-8020(09)70814-4", "20082990"]}, {"Citation": "Haque ME, et al. Targeting the microglial NLRP3 inflammasome and its role in Parkinson\u2019s disease. Mov. Disord. 2020;35:20\u201333. doi: 10.1002/mds.27874.", "ArticleIdList": ["10.1002/mds.27874", "31680318"]}, {"Citation": "Labzin LI, Heneka MT, Latz E. Innate immunity and neurodegeneration. Annu. Rev. Med. 2018;69:437\u2013449. doi: 10.1146/annurev-med-050715-104343.", "ArticleIdList": ["10.1146/annurev-med-050715-104343", "29106805"]}, {"Citation": "Earls RH, et al. Intrastriatal injection of preformed alpha-synuclein fibrils alters central and peripheral immune cell profiles in non-transgenic mice. J. Neuroinflammation. 2019;16:250. doi: 10.1186/s12974-019-1636-8.", "ArticleIdList": ["10.1186/s12974-019-1636-8", "PMC6889316", "31796095"]}, {"Citation": "Kuhbandner K, et al. Alpha-synuclein: a modulator during inflammatory CNS demyelination. J. Mol. Neurosci. 2020;70:1038\u20131049. doi: 10.1007/s12031-020-01498-8.", "ArticleIdList": ["10.1007/s12031-020-01498-8", "PMC7334286", "32207050"]}, {"Citation": "Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 2018;281:8\u201327. doi: 10.1111/imr.12621.", "ArticleIdList": ["10.1111/imr.12621", "PMC5756628", "29247995"]}, {"Citation": "McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson\u2019s and Alzheimer\u2019s disease brains. Neurology. 1988;38:1285\u20131291. doi: 10.1212/WNL.38.8.1285.", "ArticleIdList": ["10.1212/WNL.38.8.1285", "3399080"]}, {"Citation": "McGeer PL, McGeer EG. Inflammation and the degenerative diseases of aging. Ann. N. Y Acad. Sci. 2004;1035:104\u2013116. doi: 10.1196/annals.1332.007.", "ArticleIdList": ["10.1196/annals.1332.007", "15681803"]}, {"Citation": "Ambrosi G, et al. Complex changes in the innate and adaptive immunity accompany progressive degeneration of the nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine in the rat. Neurotox. Res. 2017;32:71\u201381. doi: 10.1007/s12640-017-9712-2.", "ArticleIdList": ["10.1007/s12640-017-9712-2", "28285346"]}, {"Citation": "Singh SS, et al. NF-\u03baB-mediated neuroinflammation in Parkinson\u2019s disease and potential therapeutic effect of polyphenols. Neurotox. Res. 2020;37:491\u2013507. doi: 10.1007/s12640-019-00147-2.", "ArticleIdList": ["10.1007/s12640-019-00147-2", "31823227"]}, {"Citation": "Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol. Neurobiol. 2016;53:1181\u20131194. doi: 10.1007/s12035-014-9070-5.", "ArticleIdList": ["10.1007/s12035-014-9070-5", "25598354"]}, {"Citation": "Hunot S, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson\u2019s disease. Neuroscience. 1996;72:355\u2013363. doi: 10.1016/0306-4522(95)00578-1.", "ArticleIdList": ["10.1016/0306-4522(95)00578-1", "8737406"]}, {"Citation": "Noelker, C. et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 3, 1393 (2013).", "ArticleIdList": ["PMC3589722", "23462811"]}, {"Citation": "Sommer A, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson\u2019s disease. Cell Stem Cell. 2018;23:123\u2013131.e126. doi: 10.1016/j.stem.2018.06.015.", "ArticleIdList": ["10.1016/j.stem.2018.06.015", "29979986"]}, {"Citation": "Galiano-Landeira J, Torra A, Vila M, Bov\u00e9 J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson\u2019s disease. Brain. 2020;143:3717\u20133733. doi: 10.1093/brain/awaa269.", "ArticleIdList": ["10.1093/brain/awaa269", "33118032"]}, {"Citation": "Karikari AA, et al. Neurodegeneration by \u03b1-synuclein-specific T cells in AAV-A53T-\u03b1-synuclein Parkinson\u2019s disease mice. Brain Behav. Immun. 2022;101:194\u2013210. doi: 10.1016/j.bbi.2022.01.007.", "ArticleIdList": ["10.1016/j.bbi.2022.01.007", "35032575"]}, {"Citation": "Karikari, A. A. et al. Neurodegeneration by \u03b1-synuclein-specific T cells in AAV-A53T-\u03b1-synuclein Parkinson\u2019s disease mice. Brain Behav Immun 101, 194-210 (2022).", "ArticleIdList": ["35032575"]}, {"Citation": "Williams GP, et al. CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson\u2019s disease. Brain. 2021;144:2047\u20132059. doi: 10.1093/brain/awab103.", "ArticleIdList": ["10.1093/brain/awab103", "PMC8370411", "33704423"]}, {"Citation": "Heiss CN, Olofsson LE. The role of the gut microbiota in development, function and disorders of the central nervous system and the enteric nervous system. J. Neuroendocrinol. 2019;31:e12684. doi: 10.1111/jne.12684.", "ArticleIdList": ["10.1111/jne.12684", "30614568"]}, {"Citation": "Lahiri S, et al. The gut microbiota influences skeletal muscle mass and function in mice. Sci. Transl. Med. 2019;11:eaan5662. doi: 10.1126/scitranslmed.aan5662.", "ArticleIdList": ["10.1126/scitranslmed.aan5662", "PMC7501733", "31341063"]}, {"Citation": "Schwiertz A, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 2018;50:104\u2013107. doi: 10.1016/j.parkreldis.2018.02.022.", "ArticleIdList": ["10.1016/j.parkreldis.2018.02.022", "29454662"]}, {"Citation": "Patterson AM, et al. Human gut symbiont Roseburia hominis promotes and regulates innate immunity. Front. Immunol. 2017;8:1166. doi: 10.3389/fimmu.2017.01166.", "ArticleIdList": ["10.3389/fimmu.2017.01166", "PMC5622956", "29018440"]}, {"Citation": "Matheoud D, et al. Intestinal infection triggers Parkinson\u2019s disease-like symptoms in Pink1(-/-) mice. Nature. 2019;571:565\u2013569. doi: 10.1038/s41586-019-1405-y.", "ArticleIdList": ["10.1038/s41586-019-1405-y", "31316206"]}, {"Citation": "Kelly LP, et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson\u2019s disease. Mov. Disord. 2014;29:999\u20131009. doi: 10.1002/mds.25736.", "ArticleIdList": ["10.1002/mds.25736", "PMC4050039", "24898698"]}, {"Citation": "Gorecki AM, et al. Altered gut microbiome in Parkinson\u2019s disease and the influence of lipopolysaccharide in a human \u03b1-synuclein over-expressing mouse model. Front. Neurosci. 2019;13:839. doi: 10.3389/fnins.2019.00839.", "ArticleIdList": ["10.3389/fnins.2019.00839", "PMC6693556", "31440136"]}, {"Citation": "Chen SG, et al. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged Fischer 344 rats and Caenorhabditis elegans. Sci. Rep. 2016;6:34477. doi: 10.1038/srep34477.", "ArticleIdList": ["10.1038/srep34477", "PMC5052651", "27708338"]}, {"Citation": "Challis C, et al. Gut-seeded \u03b1-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat. Neurosci. 2020;23:327\u2013336. doi: 10.1038/s41593-020-0589-7.", "ArticleIdList": ["10.1038/s41593-020-0589-7", "PMC7065967", "32066981"]}, {"Citation": "Kim S, et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron. 2019;103:627\u2013641.e627. doi: 10.1016/j.neuron.2019.05.035.", "ArticleIdList": ["10.1016/j.neuron.2019.05.035", "PMC6706297", "31255487"]}, {"Citation": "Uemura N, et al. Inoculation of \u03b1-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve. Mol. Neurodegener. 2018;13:21. doi: 10.1186/s13024-018-0257-5.", "ArticleIdList": ["10.1186/s13024-018-0257-5", "PMC5948849", "29751824"]}, {"Citation": "Van Den Berge N, et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol. 2019;138:535\u2013550. doi: 10.1007/s00401-019-02040-w.", "ArticleIdList": ["10.1007/s00401-019-02040-w", "PMC6778265", "31254094"]}, {"Citation": "Arotcarena ML, et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain. 2020;143:1462\u20131475. doi: 10.1093/brain/awaa096.", "ArticleIdList": ["10.1093/brain/awaa096", "32380543"]}, {"Citation": "Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat. Disord. 2018;46:S30\u2013s33. doi: 10.1016/j.parkreldis.2017.07.033.", "ArticleIdList": ["10.1016/j.parkreldis.2017.07.033", "PMC5718208", "28780180"]}, {"Citation": "Schober A. Classic toxin-induced animal models of Parkinson\u2019s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318:215\u2013224. doi: 10.1007/s00441-004-0938-y.", "ArticleIdList": ["10.1007/s00441-004-0938-y", "15503155"]}, {"Citation": "Vandamme TF. Use of rodents as models of human diseases. J. Pharm. Bioallied Sci. 2014;6:2\u20139. doi: 10.4103/0975-7406.124301.", "ArticleIdList": ["10.4103/0975-7406.124301", "PMC3895289", "24459397"]}, {"Citation": "Ding F, et al. Development of a stable, early stage unilateral model of Parkinson\u2019s disease in middle-aged rhesus monkeys. Exp. Neurol. 2008;212:431\u2013439. doi: 10.1016/j.expneurol.2008.04.027.", "ArticleIdList": ["10.1016/j.expneurol.2008.04.027", "PMC2527750", "18547564"]}, {"Citation": "Kuwahara T, et al. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 2006;281:334\u2013340. doi: 10.1074/jbc.M504860200.", "ArticleIdList": ["10.1074/jbc.M504860200", "16260788"]}, {"Citation": "Lakso M, et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 2003;86:165\u2013172. doi: 10.1046/j.1471-4159.2003.01809.x.", "ArticleIdList": ["10.1046/j.1471-4159.2003.01809.x", "12807436"]}, {"Citation": "Feany MB, Bender WW. A Drosophila model of Parkinson\u2019s disease. Nature. 2000;404:394\u2013398. doi: 10.1038/35006074.", "ArticleIdList": ["10.1038/35006074", "10746727"]}, {"Citation": "Chesselet MF. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson\u2019s disease? Exp. Neurol. 2008;209:22\u201327. doi: 10.1016/j.expneurol.2007.08.006.", "ArticleIdList": ["10.1016/j.expneurol.2007.08.006", "PMC2262051", "17949715"]}, {"Citation": "Dawson T, Mandir A, Lee M. Animal models of PD: pieces of the same puzzle? Neuron. 2002;35:219\u2013222. doi: 10.1016/S0896-6273(02)00780-8.", "ArticleIdList": ["10.1016/S0896-6273(02)00780-8", "12160740"]}, {"Citation": "Giasson BI, et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521\u2013533. doi: 10.1016/S0896-6273(02)00682-7.", "ArticleIdList": ["10.1016/S0896-6273(02)00682-7", "12062037"]}, {"Citation": "Lee MK, et al. Human alpha-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl Acad. Sci. USA. 2002;99:8968\u20138973. doi: 10.1073/pnas.132197599.", "ArticleIdList": ["10.1073/pnas.132197599", "PMC124407", "12084935"]}, {"Citation": "Ekstrand MI, et al. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum. Mol. Genet. 2004;13:935\u2013944. doi: 10.1093/hmg/ddh109.", "ArticleIdList": ["10.1093/hmg/ddh109", "15016765"]}, {"Citation": "Gr\u00fcnewald A, Kumar KR, Sue CM. New insights into the complex role of mitochondria in Parkinson\u2019s disease. Prog. Neurobiol. 2019;177:73\u201393. doi: 10.1016/j.pneurobio.2018.09.003.", "ArticleIdList": ["10.1016/j.pneurobio.2018.09.003", "30219247"]}, {"Citation": "Luk KC, et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA. 2009;106:20051\u201320056. doi: 10.1073/pnas.0908005106.", "ArticleIdList": ["10.1073/pnas.0908005106", "PMC2785290", "19892735"]}, {"Citation": "Volpicelli-Daley LA, et al. Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57\u201371. doi: 10.1016/j.neuron.2011.08.033.", "ArticleIdList": ["10.1016/j.neuron.2011.08.033", "PMC3204802", "21982369"]}, {"Citation": "Luk KC, et al. Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice. J. Exp. Med. 2012;209:975\u2013986. doi: 10.1084/jem.20112457.", "ArticleIdList": ["10.1084/jem.20112457", "PMC3348112", "22508839"]}, {"Citation": "Luk KC, et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949\u2013953. doi: 10.1126/science.1227157.", "ArticleIdList": ["10.1126/science.1227157", "PMC3552321", "23161999"]}, {"Citation": "Paumier KL, et al. Intrastriatal injection of pre-formed mouse \u03b1-synuclein fibrils into rats triggers \u03b1-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol. Dis. 2015;82:185\u2013199. doi: 10.1016/j.nbd.2015.06.003.", "ArticleIdList": ["10.1016/j.nbd.2015.06.003", "PMC4640952", "26093169"]}, {"Citation": "Abdelmotilib H, et al. \u03b1-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration. Neurobiol. Dis. 2017;105:84\u201398. doi: 10.1016/j.nbd.2017.05.014.", "ArticleIdList": ["10.1016/j.nbd.2017.05.014", "PMC5701756", "28576704"]}, {"Citation": "Gray R, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196\u20131205. doi: 10.1016/S0140-6736(14)60683-8.", "ArticleIdList": ["10.1016/S0140-6736(14)60683-8", "24928805"]}, {"Citation": "LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: a look backward and forward. Neurology. 2016;86:S3\u2013S12. doi: 10.1212/WNL.0000000000002509.", "ArticleIdList": ["10.1212/WNL.0000000000002509", "27044648"]}, {"Citation": "Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson\u2019s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677\u2013687. doi: 10.1016/S1474-4422(06)70521-X.", "ArticleIdList": ["10.1016/S1474-4422(06)70521-X", "16857573"]}, {"Citation": "Cenci MA. Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol. 2014;5:242. doi: 10.3389/fneur.2014.00242.", "ArticleIdList": ["10.3389/fneur.2014.00242", "PMC4266027", "25566170"]}, {"Citation": "Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov. Disord. 2015;30:114\u2013120. doi: 10.1002/mds.26078.", "ArticleIdList": ["10.1002/mds.26078", "25476691"]}, {"Citation": "Fox SH, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson\u2019s disease. Mov. Disord. 2011;26:S2\u2013S41. doi: 10.1002/mds.23829.", "ArticleIdList": ["10.1002/mds.23829", "22021173"]}, {"Citation": "Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. J. Am. Med. Assoc. 2014;311:1670\u20131683. doi: 10.1001/jama.2014.3654.", "ArticleIdList": ["10.1001/jama.2014.3654", "24756517"]}, {"Citation": "Seppi K, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov. Disord. 2011;26:S42\u2013S80. doi: 10.1002/mds.23884.", "ArticleIdList": ["10.1002/mds.23884", "PMC4020145", "22021174"]}, {"Citation": "Jankovic J, Poewe W. Therapies in Parkinson\u2019s disease. Curr. Opin. Neurol. 2012;25:433\u2013447. doi: 10.1097/WCO.0b013e3283542fc2.", "ArticleIdList": ["10.1097/WCO.0b013e3283542fc2", "22691758"]}, {"Citation": "Voon V, Mehta AR, Hallett M. Impulse control disorders in Parkinson\u2019s disease: recent advances. Curr. Opin. Neurol. 2011;24:324\u2013330. doi: 10.1097/WCO.0b013e3283489687.", "ArticleIdList": ["10.1097/WCO.0b013e3283489687", "PMC3154756", "21725242"]}, {"Citation": "Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry. 1990;53:96\u2013101. doi: 10.1136/jnnp.53.2.96.", "ArticleIdList": ["10.1136/jnnp.53.2.96", "PMC487943", "2313313"]}, {"Citation": "Katzenschlager R, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson\u2019s disease: a prospective study using single-dose challenges. Mov. Disord. 2005;20:151\u2013157. doi: 10.1002/mds.20276.", "ArticleIdList": ["10.1002/mds.20276", "15390035"]}, {"Citation": "Hauser RA, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson\u2019s disease. Mov. Disord. 2016;31:1366\u20131372. doi: 10.1002/mds.26697.", "ArticleIdList": ["10.1002/mds.26697", "27430123"]}, {"Citation": "M\u00fcller T. Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs. 2015;75:157\u2013174. doi: 10.1007/s40265-014-0343-0.", "ArticleIdList": ["10.1007/s40265-014-0343-0", "25559423"]}, {"Citation": "Ferreira JJ, et al. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154\u2013165. doi: 10.1016/S1474-4422(15)00336-1.", "ArticleIdList": ["10.1016/S1474-4422(15)00336-1", "26725544"]}, {"Citation": "Schapira AH. Monoamine oxidase B inhibitors for the treatment of Parkinson\u2019s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061\u20131071. doi: 10.2165/11596310-000000000-00000.", "ArticleIdList": ["10.2165/11596310-000000000-00000", "22133327"]}, {"Citation": "Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with \u2018Madopar\u2019 and L-deprenil in Parkinson\u2019s disease. A long-term study. Lancet. 1977;1:439\u2013443. doi: 10.1016/S0140-6736(77)91940-7.", "ArticleIdList": ["10.1016/S0140-6736(77)91940-7", "65560"]}, {"Citation": "Schapira AH, et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:216\u2013224. doi: 10.1001/jamaneurol.2016.4467.", "ArticleIdList": ["10.1001/jamaneurol.2016.4467", "27942720"]}, {"Citation": "Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464\u2013474. doi: 10.1016/S1474-4422(09)70068-7.", "ArticleIdList": ["10.1016/S1474-4422(09)70068-7", "19375664"]}, {"Citation": "Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson\u2019s disease. Neurotherapeutics. 2014;11:78\u201391. doi: 10.1007/s13311-013-0238-x.", "ArticleIdList": ["10.1007/s13311-013-0238-x", "PMC3899484", "24288035"]}, {"Citation": "Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson\u2019s disease. Expert Opin. Emerg. Drugs. 2013;18:39\u201353. doi: 10.1517/14728214.2013.766168.", "ArticleIdList": ["10.1517/14728214.2013.766168", "23373820"]}, {"Citation": "Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray D. PF-06649751 efficacy and safety in early Parkinson\u2019s disease: a randomized, placebo-controlled trial. Ther. Adv. Neurol. Disord. 2020;13:1756286420911296. doi: 10.1177/1756286420911296.", "ArticleIdList": ["10.1177/1756286420911296", "PMC7066585", "32201505"]}, {"Citation": "Svenningsson P, et al. Safety and tolerability of IRL790 in Parkinson\u2019s disease with levodopa-induced dyskinesia-a phase 1b trial. NPJ Parkinsons Dis. 2018;4:35. doi: 10.1038/s41531-018-0071-3.", "ArticleIdList": ["10.1038/s41531-018-0071-3", "PMC6283839", "30534585"]}, {"Citation": "Devos D, et al. Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid. Redox Signal. 2014;21:195\u2013210. doi: 10.1089/ars.2013.5593.", "ArticleIdList": ["10.1089/ars.2013.5593", "PMC4060813", "24251381"]}, {"Citation": "Martin-Bastida A, et al. Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci. Rep. 2017;7:1398. doi: 10.1038/s41598-017-01402-2.", "ArticleIdList": ["10.1038/s41598-017-01402-2", "PMC5431100", "28469157"]}, {"Citation": "Hung, L. W. et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson\u2019s disease. J Exp Med 209, 837-854 (2012).", "ArticleIdList": ["PMC3328361", "22473957"]}, {"Citation": "Pagano G, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 2022;387:421\u2013432. doi: 10.1056/NEJMoa2202867.", "ArticleIdList": ["10.1056/NEJMoa2202867", "35921451"]}, {"Citation": "Yang J, Song S, Li J, Liang T. Neuroprotective effect of curcumin on hippocampal injury in 6-OHDA-induced Parkinson\u2019s disease rat. Pathol. Res. Pr. 2014;210:357\u2013362. doi: 10.1016/j.prp.2014.02.005.", "ArticleIdList": ["10.1016/j.prp.2014.02.005", "24642369"]}, {"Citation": "Baj T, Seth R. Role of curcumin in regulation of TNF-\u03b1 mediated brain inflammatory responses. Recent Pat. Inflamm. Allergy Drug Discov. 2018;12:69\u201377. doi: 10.2174/1872213X12666180703163824.", "ArticleIdList": ["10.2174/1872213X12666180703163824", "29972106"]}, {"Citation": "El Nebrisi E, Javed H, Ojha SK, Oz M, Shehab S. Neuroprotective effect of curcumin on the nigrostriatal pathway in a 6-hydroxydopmine-induced rat model of Parkinson\u2019s disease is mediated by \u03b17-nicotinic receptors. Int. J. Mol. Sci. 2020;21:7329. doi: 10.3390/ijms21197329.", "ArticleIdList": ["10.3390/ijms21197329", "PMC7583812", "33023066"]}, {"Citation": "Cre\u0163u E, Trifan A, Vasincu A, Miron A. Plant-derived anticancer agents\u2014curcumin in cancer prevention and treatment. Rev. Med. Chir. Soc. Med Nat. Iasi. 2012;116:1223\u20131229.", "ArticleIdList": ["23700916"]}, {"Citation": "Ghasemi F, Bagheri H, Barreto GE, Read MI, Sahebkar A. Effects of curcumin on microglial cells. Neurotox. Res. 2019;36:12\u201326. doi: 10.1007/s12640-019-00030-0.", "ArticleIdList": ["10.1007/s12640-019-00030-0", "30949950"]}, {"Citation": "Fan C, et al. Neuroprotective effects of curcumin on il-1\u03b2-induced neuronal apoptosis and depression-like behaviors caused by chronic stress in rats. Front. Cell Neurosci. 2018;12:516. doi: 10.3389/fncel.2018.00516.", "ArticleIdList": ["10.3389/fncel.2018.00516", "PMC6330766", "30666189"]}, {"Citation": "Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. Food Chem. Toxicol. 2015;83:111\u2013124. doi: 10.1016/j.fct.2015.05.022.", "ArticleIdList": ["10.1016/j.fct.2015.05.022", "26066364"]}, {"Citation": "Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin. Exp. Pharm. Physiol. 2012;39:283\u2013299. doi: 10.1111/j.1440-1681.2011.05648.x.", "ArticleIdList": ["10.1111/j.1440-1681.2011.05648.x", "PMC3288651", "22118895"]}, {"Citation": "Sharma N, Nehru B. Curcumin affords neuroprotection and inhibits \u03b1-synuclein aggregation in lipopolysaccharide-induced Parkinson\u2019s disease model. Inflammopharmacology. 2018;26:349\u2013360. doi: 10.1007/s10787-017-0402-8.", "ArticleIdList": ["10.1007/s10787-017-0402-8", "29027056"]}, {"Citation": "Albani D, et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 2009;110:1445\u20131456. doi: 10.1111/j.1471-4159.2009.06228.x.", "ArticleIdList": ["10.1111/j.1471-4159.2009.06228.x", "19558452"]}, {"Citation": "Zhang J, et al. Resveratrol protects PC12 cell against 6-OHDA damage via CXCR4 signaling pathway. Evid. Based Complement Altern. Med. 2015;2015:730121. doi: 10.1155/2015/730121.", "ArticleIdList": ["10.1155/2015/730121", "PMC4670657", "26681969"]}, {"Citation": "Zeng W, Zhang W, Lu F, Gao L, Gao G. Resveratrol attenuates MPP(+)-induced mitochondrial dysfunction and cell apoptosis via AKT/GSK-3\u03b2 pathway in SN4741 cells. Neurosci. Lett. 2017;637:50\u201356. doi: 10.1016/j.neulet.2016.11.054.", "ArticleIdList": ["10.1016/j.neulet.2016.11.054", "27894919"]}, {"Citation": "Wang H, et al. Resveratrol suppresses rotenone-induced neurotoxicity through activation of SIRT1/Akt1 signaling pathway. Anat. Rec. 2018;301:1115\u20131125. doi: 10.1002/ar.23781.", "ArticleIdList": ["10.1002/ar.23781", "29350822"]}, {"Citation": "Huang N, et al. Resveratrol delays 6-hydroxydopamine-induced apoptosis by activating the PI3K/Akt signaling pathway. Exp. Gerontol. 2019;124:110653. doi: 10.1016/j.exger.2019.110653.", "ArticleIdList": ["10.1016/j.exger.2019.110653", "31295526"]}, {"Citation": "Abolaji AO, Adedara AO, Adie MA, Vicente-Crespo M, Farombi EO. Resveratrol prolongs lifespan and improves 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced oxidative damage and behavioural deficits in Drosophila melanogaster. Biochem. Biophys. Res. Commun. 2018;503:1042\u20131048. doi: 10.1016/j.bbrc.2018.06.114.", "ArticleIdList": ["10.1016/j.bbrc.2018.06.114", "29935183"]}, {"Citation": "Lin KL, et al. Resveratrol provides neuroprotective effects through modulation of mitochondrial dynamics and ERK1/2 regulated autophagy. Free Radic. Res. 2018;52:1371\u20131386. doi: 10.1080/10715762.2018.1489128.", "ArticleIdList": ["10.1080/10715762.2018.1489128", "30693838"]}, {"Citation": "Palle S, Neerati P. Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson\u2019s disease. Naunyn Schmiedebergs Arch. Pharm. 2018;391:445\u2013453. doi: 10.1007/s00210-018-1474-8.", "ArticleIdList": ["10.1007/s00210-018-1474-8", "29411055"]}, {"Citation": "Peng K, et al. Resveratrol regulates mitochondrial biogenesis and fission/fusion to attenuate rotenone-induced neurotoxicity. Oxid. Med. Cell Longev. 2016;2016:6705621. doi: 10.1155/2016/6705621.", "ArticleIdList": ["10.1155/2016/6705621", "PMC4684867", "26770656"]}, {"Citation": "Guo YJ, et al. Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of \u03b1-synuclein via SIRT1-deacetylated LC3. Mol. Nutr. Food Res. 2016;60:2161\u20132175. doi: 10.1002/mnfr.201600111.", "ArticleIdList": ["10.1002/mnfr.201600111", "PMC6089356", "27296520"]}, {"Citation": "Liu Q, et al. Resveratrol synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson disease in mice. Behav. Brain Res. 2019;367:10\u201318. doi: 10.1016/j.bbr.2019.03.043.", "ArticleIdList": ["10.1016/j.bbr.2019.03.043", "30922940"]}, {"Citation": "Lin TK, et al. Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy. Int. J. Mol. Sci. 2014;15:1625\u20131646. doi: 10.3390/ijms15011625.", "ArticleIdList": ["10.3390/ijms15011625", "PMC3907890", "24451142"]}, {"Citation": "Deng H, Ma Z. Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice. Food Funct. 2021;12:8366\u20138375. doi: 10.1039/D1FO01360B.", "ArticleIdList": ["10.1039/D1FO01360B", "34342315"]}, {"Citation": "Dulovic M, et al. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol. Dis. 2014;63:1\u201311. doi: 10.1016/j.nbd.2013.11.002.", "ArticleIdList": ["10.1016/j.nbd.2013.11.002", "24269733"]}, {"Citation": "Hou YS, et al. Sestrin2 protects dopaminergic cells against rotenone toxicity through AMPK-dependent autophagy activation. Mol. Cell Biol. 2015;35:2740\u20132751. doi: 10.1128/MCB.00285-15.", "ArticleIdList": ["10.1128/MCB.00285-15", "PMC4508325", "26031332"]}, {"Citation": "Huang S, et al. Berberine protects against NLRP3 inflammasome via ameliorating autophagic impairment in MPTP-induced Parkinson\u2019s disease model. Front. Pharm. 2020;11:618787. doi: 10.3389/fphar.2020.618787.", "ArticleIdList": ["10.3389/fphar.2020.618787", "PMC7872967", "33584302"]}, {"Citation": "Wang Y, et al. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson\u2019s disease by regulating gut microbiota. Signal Transduct. Target Ther. 2021;6:77. doi: 10.1038/s41392-020-00456-5.", "ArticleIdList": ["10.1038/s41392-020-00456-5", "PMC7902645", "33623004"]}, {"Citation": "Zhu Y, et al. New opportunities and challenges of natural products research: when target identification meets single-cell multiomics. Acta Pharm. Sin. B. 2022;12:4011\u20134039. doi: 10.1016/j.apsb.2022.08.022.", "ArticleIdList": ["10.1016/j.apsb.2022.08.022", "PMC9643300", "36386472"]}, {"Citation": "Lu JH, et al. Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy. 2012;8:98\u2013108. doi: 10.4161/auto.8.1.18313.", "ArticleIdList": ["10.4161/auto.8.1.18313", "22113202"]}, {"Citation": "Li XM, Zhang XJ, Dong MX. Isorhynchophylline attenuates MPP(+)-induced apoptosis through endoplasmic reticulum stress- and mitochondria-dependent pathways in PC12 cells: involvement of antioxidant activity. Neuromolecular Med. 2017;19:480\u2013492. doi: 10.1007/s12017-017-8462-x.", "ArticleIdList": ["10.1007/s12017-017-8462-x", "28822073"]}, {"Citation": "Hu X, et al. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J. Neurosci. 2011;31:247\u2013261. doi: 10.1523/JNEUROSCI.4589-10.2011.", "ArticleIdList": ["10.1523/JNEUROSCI.4589-10.2011", "PMC3078571", "21209210"]}, {"Citation": "Kim SM, et al. Neuroprotective effects of black soybean anthocyanins via inactivation of ASK1-JNK/p38 pathways and mobilization of cellular sialic acids. Life Sci. 2012;90:874\u2013882. doi: 10.1016/j.lfs.2012.04.025.", "ArticleIdList": ["10.1016/j.lfs.2012.04.025", "22575822"]}, {"Citation": "Lee KW, et al. Apoptosis signal-regulating kinase 1 mediates MPTP toxicity and regulates glial activation. PLoS ONE. 2012;7:e29935. doi: 10.1371/journal.pone.0029935.", "ArticleIdList": ["10.1371/journal.pone.0029935", "PMC3254627", "22253830"]}, {"Citation": "Li X, Zhang J, Zhang X, Dong M. Puerarin suppresses MPP(+)/MPTP-induced oxidative stress through an Nrf2-dependent mechanism. Food Chem. Toxicol. 2020;144:111644. doi: 10.1016/j.fct.2020.111644.", "ArticleIdList": ["10.1016/j.fct.2020.111644", "32763437"]}, {"Citation": "Shiying L, et al. Puerarin promoted proliferation and differentiation of dopamine-producing cells in Parkinson\u2019s animal models. Biomed. Pharmacother. 2018;106:1236\u20131242. doi: 10.1016/j.biopha.2018.07.058.", "ArticleIdList": ["10.1016/j.biopha.2018.07.058", "30119192"]}, {"Citation": "Zhao Y, et al. Botanical drug puerarin promotes neuronal survival and neurite outgrowth against MPTP/MPP(+)-induced toxicity via progesterone receptor signaling. Oxid. Med. Cell Longev. 2020;2020:7635291. doi: 10.1155/2020/7635291.", "ArticleIdList": ["10.1155/2020/7635291", "PMC7586160", "33123315"]}, {"Citation": "Ji Y, Wang D, Zhang B, Lu H. Bergenin ameliorates MPTP-induced Parkinson\u2019s disease by activating PI3K/Akt signaling pathway. J. Alzheimers Dis. 2019;72:823\u2013833. doi: 10.3233/JAD-190870.", "ArticleIdList": ["10.3233/JAD-190870", "31658061"]}, {"Citation": "Luo S, et al. Akt phosphorylates NQO1 and triggers its degradation, abolishing its antioxidative activities in Parkinson\u2019s disease. J. Neurosci. 2019;39:7291\u20137305. doi: 10.1523/JNEUROSCI.0625-19.2019.", "ArticleIdList": ["10.1523/JNEUROSCI.0625-19.2019", "PMC6759025", "31358653"]}, {"Citation": "Yang L, Wang H, Liu L, Xie A. The role of insulin/IGF-1/PI3K/Akt/GSK3\u03b2 signaling in Parkinson\u2019s disease dementia. Front. Neurosci. 2018;12:73. doi: 10.3389/fnins.2018.00073.", "ArticleIdList": ["10.3389/fnins.2018.00073", "PMC5826217", "29515352"]}, {"Citation": "Zhu G, Wang X, Wu S, Li Q. Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int. 2012;60:400\u2013408. doi: 10.1016/j.neuint.2012.01.003.", "ArticleIdList": ["10.1016/j.neuint.2012.01.003", "22265823"]}, {"Citation": "Rui W, Li S, Xiao H, Xiao M, Shi J. Baicalein attenuates neuroinflammation by inhibiting NLRP3/caspase-1/GSDMD pathway in MPTP induced mice model of Parkinson\u2019s disease. Int. J. Neuropsychopharmacol. 2020;23:762\u2013773. doi: 10.1093/ijnp/pyaa060.", "ArticleIdList": ["10.1093/ijnp/pyaa060", "PMC7745250", "32761175"]}, {"Citation": "Cookson BT, Brennan MA. Pro-inflammatory programmed cell death. Trends Microbiol. 2001;9:113\u2013114. doi: 10.1016/S0966-842X(00)01936-3.", "ArticleIdList": ["10.1016/S0966-842X(00)01936-3", "11303500"]}, {"Citation": "Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 2009;7:99\u2013109. doi: 10.1038/nrmicro2070.", "ArticleIdList": ["10.1038/nrmicro2070", "PMC2910423", "19148178"]}, {"Citation": "Gordon R, et al. Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med. 2018;10:eaah4066. doi: 10.1126/scitranslmed.aah4066.", "ArticleIdList": ["10.1126/scitranslmed.aah4066", "PMC6483075", "30381407"]}, {"Citation": "Franchi L, Eigenbrod T, Mu\u00f1oz-Planillo R, Nu\u00f1ez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 2009;10:241\u2013247. doi: 10.1038/ni.1703.", "ArticleIdList": ["10.1038/ni.1703", "PMC2820724", "19221555"]}, {"Citation": "Zhao D, Wu Y, Zhuang J, Xu C, Zhang F. Activation of NLRP1 and NLRP3 inflammasomes contributed to cyclic stretch-induced pyroptosis and release of IL-1\u03b2 in human periodontal ligament cells. Oncotarget. 2016;7:68292\u201368302. doi: 10.18632/oncotarget.11944.", "ArticleIdList": ["10.18632/oncotarget.11944", "PMC5356555", "27626170"]}, {"Citation": "Chen X, et al. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 2016;26:1007\u20131020. doi: 10.1038/cr.2016.100.", "ArticleIdList": ["10.1038/cr.2016.100", "PMC5034106", "27573174"]}, {"Citation": "Wu DM, et al. Salidroside protection against oxidative stress injury through the Wnt/\u03b2-catenin signaling pathway in rats with Parkinson\u2019s disease. Cell Physiol. Biochem. 2018;46:1793\u20131806. doi: 10.1159/000489365.", "ArticleIdList": ["10.1159/000489365", "29705802"]}, {"Citation": "Zhao X, et al. Baicalein alleviates depression-like behavior in rotenone- induced Parkinson\u2019s disease model in mice through activating the BDNF/TrkB/CREB pathway. Biomed. Pharmacother. 2021;140:111556. doi: 10.1016/j.biopha.2021.111556.", "ArticleIdList": ["10.1016/j.biopha.2021.111556", "34087694"]}, {"Citation": "Zheng ZV, et al. Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism. J. Clin. Neurosci. 2019;64:242\u2013251. doi: 10.1016/j.jocn.2019.02.005.", "ArticleIdList": ["10.1016/j.jocn.2019.02.005", "30905662"]}, {"Citation": "Song JX, et al. Baicalein antagonizes rotenone-induced apoptosis in dopaminergic SH-SY5Y cells related to Parkinsonism. Chin. Med. 2012;7:1. doi: 10.1186/1749-8546-7-1.", "ArticleIdList": ["10.1186/1749-8546-7-1", "PMC3275529", "22264378"]}, {"Citation": "Zhang C, et al. The Nrf2-NLRP3-caspase-1 axis mediates the neuroprotective effects of Celastrol in Parkinson\u2019s disease. Redox Biol. 2021;47:102134. doi: 10.1016/j.redox.2021.102134.", "ArticleIdList": ["10.1016/j.redox.2021.102134", "PMC8487081", "34600334"]}, {"Citation": "Lin MW, Lin CC, Chen YH, Yang HB, Hung SY. Celastrol inhibits dopaminergic neuronal death of Parkinson\u2019s disease through activating mitophagy. Antioxidants. 2019;9:37. doi: 10.3390/antiox9010037.", "ArticleIdList": ["10.3390/antiox9010037", "PMC7022523", "31906147"]}, {"Citation": "Feng Y, et al. Triptolide inhibits preformed fibril-induced microglial activation by targeting the microRNA155-5p/SHIP1 pathway. Oxid. Med Cell Longev. 2019;2019:6527638. doi: 10.1155/2019/6527638.", "ArticleIdList": ["10.1155/2019/6527638", "PMC6512043", "31182996"]}, {"Citation": "Lu S, Liao QS, Tang L. MiR-155 affects osteosarcoma cell proliferation and invasion through regulating NF-\u03baB signaling pathway. Eur. Rev. Med. Pharm. Sci. 2018;22:7633\u20137639.", "ArticleIdList": ["30536304"]}, {"Citation": "Huang YY, et al. Triptolide up-regulates metabotropic glutamate receptor 5 to inhibit microglia activation in the lipopolysaccharide-induced model of Parkinson\u2019s disease. Brain Behav. Immun. 2018;71:93\u2013107. doi: 10.1016/j.bbi.2018.04.006.", "ArticleIdList": ["10.1016/j.bbi.2018.04.006", "29649522"]}, {"Citation": "Hu G, et al. Triptolide promotes the clearance of \u03b1-synuclein by enhancing autophagy in neuronal cells. Mol. Neurobiol. 2017;54:2361\u20132372. doi: 10.1007/s12035-016-9808-3.", "ArticleIdList": ["10.1007/s12035-016-9808-3", "26957304"]}, {"Citation": "Qu S, Meng X, Liu Y, Zhang X, Zhang Y. Ginsenoside Rb1 prevents MPTP-induced changes in hippocampal memory via regulation of the \u03b1-synuclein/PSD-95 pathway. Aging. 2019;11:1934\u20131964. doi: 10.18632/aging.101884.", "ArticleIdList": ["10.18632/aging.101884", "PMC6503885", "30958793"]}, {"Citation": "Li DW, et al. Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection. Neural Regen. Res. 2019;14:1814\u20131822. doi: 10.4103/1673-5374.257536.", "ArticleIdList": ["10.4103/1673-5374.257536", "PMC6585553", "31169200"]}, {"Citation": "Han Y, et al. Ginsenoside Rg3 exerts a neuroprotective effect in rotenone-induced Parkinson\u2019s disease mice via its anti-oxidative properties. Eur. J. Pharm. 2021;909:174413. doi: 10.1016/j.ejphar.2021.174413.", "ArticleIdList": ["10.1016/j.ejphar.2021.174413", "34391769"]}, {"Citation": "Schweitzer JS, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 2020;382:1926\u20131932. doi: 10.1056/NEJMoa1915872.", "ArticleIdList": ["10.1056/NEJMoa1915872", "PMC7288982", "32402162"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "5", "Day": "1"}, {"Year": "2023", "Month": "2", "Day": "13"}, {"Year": "2023", "Month": "1", "Day": "16"}, {"Year": "2023", "Month": "2", "Day": "22", "Hour": "14", "Minute": "39"}, {"Year": "2023", "Month": "2", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["36810524", "PMC9944326", "10.1038/s41392-023-01353-3", "10.1038/s41392-023-01353-3"]}}], "PubmedBookArticle": []}